Key result
Peru's hypertension care cascade remains stagnant, with ACC/AHA prevalence rising ~2% annually since 2014.
Why the study?
Prior assessments of the hypertension care cascade in Peru covered short periods and used a single diagnostic threshold.
Cross-Sectional (n=238,738)
Effect estimate: AAPC 1.92% (95% CI 0.35 to 3.52)
p-value: p=0.022
Peru's hypertension care cascade has stagnated over the past decade, indicating the country will likely miss WHO HEARTS 2030 targets without large-scale primary care interventions.
Persistent gaps in Peru's hypertension cascade warrant equity-focused primary care strengthening; leaves open whether scaled HEARTS interventions can meet 2030 targets.
Background Prior assessments of the hypertension care cascade in Peru have covered short periods and used a single diagnostic threshold. Objective To describe 11-year trends (2014–2024) in the hypertension care cascade under two contemporary criteria (2023 ESH and 2025 ACC/AHA), quantify socioeconomic inequalities, and project the cascade to 2030 relative to WHO HEARTS targets. Methods Repeated cross-sectional analysis of 238,738 adults (≥18 years) from the Peruvian Demographic and Family Health Survey (ENDES), 2014–2024. Hypertension was defined by ESH 2023 (≥140/90 mmHg or lifetime prior diagnosis) and ACC/AHA 2025 (≥130/80 mmHg or lifetime prior diagnosis). The cascade comprised awareness, pharmacological treatment, and control (<140/90 and <130/80 mmHg). Prevalences were age-standardized to the WHO World Standard Population. Joinpoint regression was applied to 23 time series and wealth-related inequalities were assessed with the Erreygers concentration index. Results Age-standardized ESH prevalence did not change significantly (AAPC 0.88%; p = 0.261), whereas ACC/AHA prevalence increased (AAPC 1.92%; p = 0.022), as did guideline discordance (AAPC 2.88%; p = 0.002); no joinpoints were identified. In 2024 (ESH), 53.6% of hypertensive adults were aware of their diagnosis, 60.3% of those diagnosed received treatment, and 59.0% of treated individuals achieved control <140/90 mmHg; population-level treatment and control were 32.3 and 19.1%. The Erreygers index indicated stronger pro-rich inequality for treatment than for awareness. Projected 2030 values for awareness, treatment, and control were 54.2, 33.5, and 21.0%, leaving gaps of 25.8, 30.5, and 30.2 percentage points relative to 80–80-80 targets. Conclusion Peru’s population-level hypertension care cascade showed persistent stagnation during 2014–2024. Current trends indicate the country will not achieve HEARTS 2030 targets without large-scale primary care interventions with an equity focus.
No takes yet. Share an insight, caveat, or question.
Ballena-Caicedo et al. (2026) conducted a cross-sectional in Hypertension (n=238,738). Survey year (2014-2024) was evaluated on Trend in age-standardized ACC/AHA hypertension prevalence (AAPC 1.92%, 95% CI 0.35 to 3.52, p=0.022). Peru's population-level hypertension care cascade showed persistent stagnation from 2014 to 2024, with age-standardized ACC/AHA hypertension prevalence increasing by an average annual percent change of 1.92%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: